220 research outputs found
Nominal Equational Logic
AbstractThis paper studies the notion of âfreshnessâ that often occurs in the meta-theory of computer science languages involving various kinds of names. Nominal Equational Logic is an extension of ordinary equational logic with assertions about the freshness of names. It is shown to be both sound and complete for the support interpretation of freshness and equality provided by the Gabbay-Pitts nominal sets model of names, binding and Îą-conversion
Multiple cerebral aneurysms in an adult with autosomal recessive polycystic kidney disease
[Extract] Autosomal recessive polycystic kidney disease(ARPKD) is a rare form offibrocystic kidneydisease that affects approximately 1 in 20,000 live births. The classic presentation is with prominenthepatic impairment caused by hepatic fibrosis in addition to renal impairment that is more aggressive than that seen in autosomal dominant polycystic kidney disease (ADPKD). Caroli syndrome is the eponymgiven to the combination of ARPKD, hepatic fibrosis, portal hypertension, and intrahepatic bile duct dilatation. It is seen in â¤50% of cases of ARPKD
Modal dependent type theory and dependent right adjoints
In recent years we have seen several new models of dependent type theory
extended with some form of modal necessity operator, including nominal type
theory, guarded and clocked type theory, and spatial and cohesive type theory.
In this paper we study modal dependent type theory: dependent type theory with
an operator satisfying (a dependent version of) the K-axiom of modal logic. We
investigate both semantics and syntax. For the semantics, we introduce
categories with families with a dependent right adjoint (CwDRA) and show that
the examples above can be presented as such. Indeed, we show that any finite
limit category with an adjunction of endofunctors gives rise to a CwDRA via the
local universe construction. For the syntax, we introduce a dependently typed
extension of Fitch-style modal lambda-calculus, show that it can be interpreted
in any CwDRA, and build a term model. We extend the syntax and semantics with
universes
Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High-Density Single-Nucleotide Polymorphism Arrays
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic profile of 23 esophageal adenocarcinoma (EAC) primary tumor biopsies based on loss of heterozygosity (LOH) and DNA copy number changes. Alterations were common, averaging 97 (range, 23-208) per tumor. LOH and gains averaged 33 (range, 3-83) and 31 (range, 11-73) per tumor, respectively. Copy neutral LOH events averaged 27 (range, 7-57) per EAC. We noted 126 homozygous deletions (HD) across the EAC panel (range, 0-11 in individual tumors). Frequent HDs within FHIT (17 of 23), WWOX (8 of 23), and DMD (6 of 23) suggest a role for common fragile sites or genomic instability in EAC etiology. HDs were also noted for known tumor suppressor genes (TSG), including CDKN2A, CDKN2B, SMAD4, and GALR1, and identified PDE4D and MGC48628 as potentially novel TSGs. All tumors showed LOH for most of chromosome 17p, suggesting that TSGs other than TP53 may be targeted. Frequent gains were noted around MYC (13 of 23), BCL9 (12 of 23), CTAGE1 (14 of 23), and ZNF217 (12 of 23). Thus, we have confirmed previous reports indicating frequent changes to FHIT, CDKN2A, TP53, and MYC in EAC and identified additional genes of interest. Meta-analysis of previous genome-wide EAC studies together with the data presented here highlighted consistent regions of gain on 8q, 18q, and 20q and multiple LOH regions on 4q, 5q, 17p, and 18q, suggesting that more than one gene may be targeted on each of these chromosome arms. The focal gains and deletions documented here are a step toward identifying the key genes involved in EAC development
A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis
Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma
Background Barrett's esophagus (BE) is the metaplastic replacement of squamous with columnar epithelium in the esophagus, as a result of reflux. It is the major risk factor for the development of esophageal adenocarcinoma (EAC). Methylation of CpG dinucleotides of normally unmethylated genes is associated with silencing of their expression, and is common in EAC. This study was designed to determine at what stage, in the progression from BE to EAC, methylation of key genes occurs. Results We examined nine genes (APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2), frequently methylated in multiple cancer types, in a panel of squamous (19 biopsies from patients without BE or EAC, 16 from patients with BE, 21 from patients with EAC), BE (40 metaplastic, seven high grade dysplastic) and 37 EAC tissues. The methylation frequency, the percentage of samples that had any extent of methylation, for each of the nine genes in the EAC (95%, 59%, 76%, 57%, 70%, 73%, 95%, 74% and 83% respectively) was significantly higher than in any of the squamous groups. The methylation frequency for each of the nine genes in the metaplastic BE (95%, 28%, 78%, 48%, 58%, 48%, 93%, 88% and 75% respectively) was significantly higher than in the squamous samples except for CDKN2A and RBP1. The methylation frequency did not differ between BE and EAC samples, except for CDKN2A and RUNX3 which were significantly higher in EAC. The methylation extent was an estimate of both the number of methylated alleles and the density of methylation on these alleles. This was significantly greater in EAC than in metaplastic BE for all genes except APC, MGMT and TIMP3. There was no significant difference in methylation extent for any gene between high grade dysplastic BE and EAC. Conclusion We found significant methylation in metaplastic BE, which for seven of the nine genes studied did not differ in frequency from that found in EAC. This is also the first report of gene silencing by methylation of ID4 in BE or EAC. This study suggests that metaplastic BE is a highly abnormal tissue, more similar to cancer tissue than to normal epithelium.Eric Smith, Neville J De Young, Sandra J Pavey, Nicholas K Hayward, Derek J Nancarrow, David C Whiteman, B Mark Smithers, Andrew R Ruszkiewicz, Andrew D Clouston, David C Gotley, Peter G Devitt, Glyn G Jamieson and Paul A Dre
Effect of COVID-19 on presentations of decompensated liver disease in Scotland
BACKGROUND AND AIMS: SARS-CoV-2 and consequent pandemic has presented unique challenges. Beyond the direct COVID-related mortality in those with liver disease, we sought to determine the effect of lockdown on people with liver disease in Scotland. The effect of lockdown on those with alcohol-related disease is of interest; and whether there were associated implications for a change in alcohol intake and consequent presentations with decompensated disease. METHODS: We performed a retrospective analysis of patients admitted to seven Scottish hospitals with a history of liver disease between 1 April and 30 April 2020 and compared across the same time in 2017, 2018 and 2019. We also repeated an intermediate assessment based on a single centre to examine for delayed effects between 1 April and 31 July 2020. RESULTS: We found that results and outcomes for patients admitted in 2020 were similar to those in previous years in terms of morbidity, mortality, and length of stay. In the Scotland-wide cohort: admission MELD (Model for End-stage Liver Disease) (16 (12â22) vs 15 (12â19); p=0.141), inpatient mortality ((10.9% vs 8.6%); p=0.499) and length of stay (8âdays (4â15) vs 7âdays (4â13); p=0.140). In the Edinburgh cohort: admission MELD (17 (12â23) vs 17 (13â21); p=0.805), inpatient mortality ((13.7% vs 10.1%; p=0.373) and length of stay (7âdays (4â14) vs 7âdays (3.5â14); p=0.525)). CONCLUSION: This assessment of immediate and medium-term lockdown impacts on those with chronic liver disease suggested a minimal effect on the presentation of decompensated liver disease to secondary care
Randomized, placebo controlled trial of experimental hookworm infection for improving gluten tolerance in Celiac disease
INTRODUCTION:
Celiac disease is an autoimmune disorder where intestinal immunopathology arises after gluten consumption. Previous studies suggested that hookworm infection restores gluten tolerance; however, these studies were small (n = 12) and not placebo controlled.
METHODS:
We undertook a randomized, placebo-controlled trial of hookworm infection in 54 people with celiac disease. The 94-week study involved treatment with either 20 or 40 Necator americanus third-stage larvae (L3-20 or L3-40) or placebo, followed by escalating gluten consumption (50 mg/d for 12 weeks, 1 g intermittent twice weekly for 12 weeks, 2 g/d sustained for 6 weeks, liberal diet for 1 year).
RESULTS:
Successful study completion rates at week 42 (primary outcome) were similar in each group (placebo: 57%, L3-20: 37%, and L3-40: 44%; P = 0.61), however gluten-related adverse events were significantly reduced in hookworm-treated participants: Median (range) adverse events/participant were as follows: placebo, 4 (1â9); L3-20, 1 (0â9); and L3-40, 0 (0â3) (P = 0.019). Duodenal villous height:crypt depth deteriorated similarly compared with their enrolment values in each group (mean change [95% confidence interval]: placebo, â0.6 [â1.3 to 0.2]; L3-20, â0.5 [â0.8 to 0.2]; and L3-40, â1.1 [â1.8 to 0.4]; P = 0.12). A retrospective analysis revealed that 9 of the 40 L3-treated participants failed to establish hookworm infections. Although week 42 completion rates were similar in hookworm-positive vs hookworm-negative participants (48% vs 44%, P = 0.43), quality of life symptom scores were lower in hookworm-positive participants after intermittent gluten challenge (mean [95% confidence interval]: 38.9 [33.9â44] vs 45.9 [39.2â52.6]).
DISCUSSION:
Hookworm infection does not restore tolerance to sustained moderate consumption of gluten (2 g/d) but was associated with improved symptom scores after intermittent consumption of lower, intermittent gluten doses
Personalized recurrence risk assessment following the birth of a child with a pathogenic de novo mutation
Following the diagnosis of a paediatric disorder caused by an apparently de novo mutation, a recurrence risk of 1â2% is frequently quoted due to the possibility of parental germline mosaicism; but for any specific couple, this figure is usually incorrect. We present a systematic approach to providing individualized recurrence risk. By combining locus-specific sequencing of multiple tissues to detect occult mosaicism with long-read sequencing to determine the parent-of-origin of the mutation, we show that we can stratify the majority of couples into one of seven discrete categories associated with substantially different risks to future offspring. Among 58 families with a single affected offspring (representing 59 de novo mutations in 49 genes), the recurrence risk for 35 (59%) was decreased below 0.1%, but increased owing to parental mixed mosaicism for 5 (9%)âthat could be quantified in semen for paternal cases (recurrence risks of 5.6â12.1%). Implementation of this strategy offers the prospect of driving a major transformation in the practice of genetic counselling
- âŚ